Publication of Tumor Marker Research Results: The Necessity for Complete and Transparent Reporting
Authors:
- 1 December 2012
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (34) , 4223-4232
Abstract
Clinical management decisions for patients with cancer are increasingly being guided by prognostic and predictive markers. Use of these markers should be based on a sufficiently comprehensive body of unbiased evidence to establish that benefits to patients outweigh harms and to justify expenditure of health care dollars. Careful assessments of the clinical utility of markers by using comparative effectiveness research methods are urgently needed to more rigorously summarize and evaluate the evidence, but multiple factors have made such assessments difficult. The literature on tumor markers is plagued by nonpublication bias, selective reporting, and incomplete reporting. Several measures to address these problems are discussed, including development of a tumor marker study registry, greater attention to assay analytic performance and specimen quality, use of more rigorous study designs and analysis plans to establish clinical utility, and adherence to higher standards for reporting tumor marker studies. More complete and transparent reporting by adhering to criteria such as BRISQ [Biospecimen Reporting for Improved Study Quality] criteria for reporting details about specimens and REMARK [Reporting Recommendations for Tumor Marker Prognostic Studies] criteria for reporting a multitude of aspects relating to study design, analysis, and results, is essential for reliable assessment of study quality, detection of potential biases, and proper interpretation of study findings. Adopting these measures will improve the quality of the body of evidence available for comparative effectiveness research and enhance the ability to establish the clinical utility of prognostic and predictive tumor markers.Keywords
This publication has 76 references indexed in Scilit:
- Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trialsThe Lancet, 2012
- Bevacizumab in the Treatment of Metastatic Breast Cancer: Friend or Foe?Current Oncology Reports, 2011
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisThe Lancet Oncology, 2011
- Biospecimen Reporting for Improved Study Quality (BRISQ)Journal of Proteome Research, 2011
- Biomarker studies: a call for a comprehensive biomarker study registryNature Reviews Clinical Oncology, 2011
- Biospecimen Reporting for Improved Study QualityBiopreservation and Biobanking, 2011
- Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelinesBritish Journal of Cancer, 2009
- The Neglected Purpose of Comparative-Effectiveness ResearchNew England Journal of Medicine, 2009
- REporting recommendations for tumour MARKer prognostic studies (REMARK)British Journal of Cancer, 2005
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000